Monthly Newsletter from the Arizona Asthma Coalition

Register Today!

16th Annual Arizona Asthma & Allergy Clinical Conference

The Arizona Asthma & Allergy Conference provides education and networking for clinicians and anyone who cares for patients living with asthma and allergies. This educational activity is designed for practicing pediatric and adult primary care providers, asthma specialists (pulmonologists and allergists), pediatric and family nurse practitioners, physician assistants, respiratory therapists, pharmacists, nurses, school nurses, quality assurance leaders, case managers, MAs, students, and anyone else involved in the care of people with asthma and allergies. CMEs and CEUs will be offered for providers including physicians, nurse practitioners, physician assistants, and nurses.


Clinical Diagnosis & Management Guidelines for Asthma

Keynote Speaker: Wayne Morgan, MD


  • Describe the use of intermittent inhaled corticosteroid therapy with respiratory tract infection in children 0-4 years of age
  • Explain the use of single maintenance and reliever therapy (SMART) in children aged 5-11 years with persistent asthma
  • Describe the use of intermittent inhaled corticosteroid therapy in children and adolescents 12 years of age and older with mild persistent asthma
  • State the goals of asthma care in children in a simplified manner that can be shared with patients and caregivers
Save Your Seat
Sponsor & Exhibitor Opportunities

School Inhaler Program a Success

Arizona is a pioneer and national example for implementing an evidence-based rescue medication school-based program, the Stock Inhalers for Schools Program. Statewide, there are approximately 475 charter, private/parochial and public schools participating the 2022-2023 academic year including: (250) schools in Pima County, (206) in Maricopa, (6) in Yavapai, Pinal and Cochise Counties, respectively.

Asthma prevalence among U.S. children is about 8.6%. In AZ, severe respiratory distress leads to lost school time and approximately 2,700 9-1-1 calls every year. About 50% of these calls result in EMS transports to the emergency department (ED) but many of these ED admissions can be prevented.

A 2-year pilot Stock Inhaler Program in Tucson showed a 20% reduction in asthma-related 9-1-1 calls and a 40% reduction in asthma-related emergency transports. The program director, Professor Lynn Gerald of the University of Arizona, spearheaded passage of legislation in 2017, H.B. 2208, “Stock Inhalers for Schools,” that allows schools across Arizona to implement this program.

The program costs about $100 - $150 per school for the medication and valved holding chambers. A template step-by-step guide and toolkit are featured on our website at:

Pima County started the program in 229 schools in the 2017-18 school year. During that time inhalers were used 1,038 times. Of these events, students returned to class in 84% of the cases. Overall, (6) 9-1-1 calls occurred to EMS, and 5 events resulted in the student being transported via EMS.

More recently, the Maricopa County Department of Public Health launched the stock albuterol inhaler program in 2018-19. Schools in this county can enroll and follow an electronic step-by-step guide at this site: For assistance or questions, contact

Other states are inquiring about how to set up programs after reading journal articles submitted by Drs. Lynn Gerald and Ashley A. Lowe. ("Guidelines for the administration of medication in school. Committee on School Health," 2003; Lowe, Gerald, et al., 2022; Lowe et al., 2021; Lowe, Phan, et al., 2022; Volerman et al., 2021)

Our goal is to expand the program to all schools statewide.

We invite you to join us stakeholder Zoom calls at noon on the 2nd Monday of each month where we share information about the program and help each other. To join, contact Lisa Rascon, M.Ed. at

Primary Contact for the Arizona Stock Inhaler Program:

Ashley A. Lowe, PhD, MSPH

University of Arizona

Guidelines for the administration of medication in school. Committee on School Health. (2003). Pediatrics, 112(3 Pt 1), 697-699.

Lowe, A. A., Gerald, J. K., Clemens, C., & Gerald, L. B. (2022). School-based Stock Inhaler Programs and Neighborhood Disadvantage. J Health Care Poor Underserved, 33(2), 1083-1093.

Lowe, A. A., Gerald, J. K., Clemens, C. J., Stern, D. A., & Gerald, L. B. (2021). Managing respiratory emergencies at school: A county-wide stock inhaler program. J Allergy Clin Immunol, 148(2), 420-427.e425.

Lowe, A. A., Phan, H., Hall-Lipsy, E., O'Shaughnessy, S., Nash, B., Volerman, A., & Gerald, L. B. (2022). School Stock Inhaler Statutes and Regulations in the United States: A Systematic Review. J Sch Health, 92(4), 396-405.

Volerman, A., Lowe, A. A., Pappalardo, A. A., Anderson, C. M. C., Blake, K. V., Bryant-Stephens, T., Carr, T., Carter, H., Cicutto, L., Gerald, J. K., Miller, T., Moore, N. S., Phan, H., Sadreameli, S. C., Tanner, A., Winders, T. A., & Gerald, L. B. (2021). Ensuring Access to Albuterol in Schools: From Policy to Implementation. An Official ATS/AANMA/ALA/NASN Policy Statement. Am J Respir Crit Care Med, 204(5), 508-522.

Climate Change & Human Health in AZ: 

What Health Pros Need to Know

Watch the webinar recording on demand!

AZ Community Grand Rounds held a session on September 7th, 2022, along with the following presenters to discuss climate change and human health in AZ.


Edward Maibach, Ph.D.

Distinguished Professor and Director of the Center of Climate Change Communication, George Mason University

Ronda Seifert, RN BSN IBCLC

Public Health Nurse, Co-Chair of Arizona Health Professionals for Climate Action

Brian Drummond, MD FAAEM

Clinical Associate Professor of Emergency Medicine, University of Arizona

Watch Here

Diagnostic Differentiation Between Asthma and COPD in Primary Care Using Lung Function Testing 

Shared from Nature

Asthma and COPD are defined as different disease entities, but in practice patients often show features of both diseases making it challenging for primary care clinicians to establish a correct diagnosis. This paper aims to establish the added value of spirometry and more advanced lung function measurements to differentiate between asthma and COPD.

Read more

American Lung Association MATCH Study Seeks Participants

The American Lung Association’s MATCH (Medication Adherence with Telehealthcare Medication Therapy Management to Change Health Outcomes in Adolescents and Young Adults with Asthma) Study is looking for participants!

The goal of this entirely virtual study--meaning anyone, anywhere can participate-- is to determine whether having regular telehealth appointments with a pharmacist will help adolescents and young adults ages 12 to 35 years old with asthma better understand and use their inhaled medications and have fewer asthma symptoms. The study lasts 1 year. Half of the participants will have telehealth calls with a pharmacist monthly for 6 visits then every 3 months for 2 more visits. All participants will have 4 virtual visits with the study site about every 3-6 months. Participants will receive a study tablet for the telehealth appointments, sensors to attach to their inhalers, and a device for breathing tests. Participants receive a stipend for their time and effort.

The study is made possible by a grant from the National, Heart, Lung and Blood Institute and the American Lung Association. The participating research institutions are part of the American Lung Association's Airways Clinical Research Centers (ACRC) Network, the nation's largest not-for-profit network of clinical centers dedicated to asthma and COPD research.

Find out more at as well as direct interested individuals to the registration form at

New Zealand Study Shows Adding Insulation to Homes Reduced Asthma 

Shared from American Journal of Managed Care

Retrofitting home insulation can reduce the onset of chronic respiratory diseases such as asthma by up to 10%, according to a new study, which said the effect was even greater in children under the age of 15. The findings come from a retrospective cohort study conducted in New Zealand, which examined the impact of a government-subsidized insulation program on respiratory health.

Read more

Open Seat on the Arizona Asthma Coalition Board

We are interested in adding a member to our board who has skill and experience in public policy and advocacy. As part of our effort to improve the health and quality of life for all asthmatics in Arizona, this new board member’s portfolio will include:

  • Networking and building relationships with coalitions and partners
  • Informing the Board and stakeholders about emerging public policies that would have an impact on people with asthma
  • Advocating for public policies which support clean air, access to healthcare and best practices for preventing and treating asthma

The successful candidate will bring a strong public health policy perspective to our board. It currently includes physicians, nurse practitioners, a school nurse manager, respiratory therapists, asthma educators, program administrators and academic faculty in pharmacy and public health.

Relevant types of experience may include:

  • Participation in local and/or statewide public health coalitions and partnerships
  • Analyzing and summarizing public policy issues in writing
  • Sharing information about policies with a statewide audience
  • Tracking proposed legislation and sharing its relevance with stakeholders
  • Representing your organization’s policy positions in presentations, media or testimony

If you are interested in being considered for this position, please send a cover letter and CV to Lisa Rascon at

Study Links Common Asthma Medication to Changes in Brain

Shared from The Hill

A new study published in The BMJ found a link between systemic and inhaled glucocorticoids— medications commonly taken for asthma and chronic obstructive pulmonary disease (COPD)— and structural and volume changes in brain gray and white matter.

Results are based on a cross-sectional study conducted among 779 individuals who took the medications and 24,106 controls enrolled in the UK Biobank between 2006 and 2010.

Read more

AstraZeneca and Amgen Severe Asthma Drug is 'One to Watch' After Phase 2 Win

Shared from Fierce Biotech

A first-in-class therapy developed by AstraZeneca and Amgen looks like a strong treatment candidate for severe uncontrolled asthma, according to a respiratory specialist. In the phase 2b PATHWAY trial, tezepelumab (AMG-157)—a first-in-class thymic stromal lymphopoietin (TSLP) antagonist—achieved a 61% to 71% reduction in the annual rate of asthma attacks depending on dose, which analysts at Jefferies say is on the higher end of the 50% to 70% efficacy range seen with competing therapies.

Read more

Follow Our Facebook Page

Arizona Asthma Coalition is now on Facebook! Head over to Facebook and like AAC to keep up to date on asthma, allergy and organizational updates in between our monthly newsletters. 

Follow us here

Join the Arizona Asthma Coalition

As a nonprofit partnership since 1996, AAC has worked together with concerned stakeholders including public health, environmental quality, managed care, education, individual physicians and nurses, hospitals, foundations, families and other colleagues. Become a member of the Arizona Asthma Coalition or renew your membership and help us continue this important work.

Join or renew here

Support AAC While You Shop!

AmazonSmile is a website operated by Amazon with the same products, prices, and shopping features as The difference is that when you shop on AmazonSmile, the AmazonSmile Foundation will donate 0.5% of the purchase price of eligible products to the charitable organization of your choice. Designate Arizona Asthma Coalition as your charity of choice and you can support our efforts to address the growing and serious problems related to asthma in Arizona.

Click here & select Arizona Asthma Coalition


Arizona Asthma Coalition | 480-289-5761

7729 E Greenway Rd, Suite 300, Scottsdale, AZ 85260